| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heterogeneous-Nuclear Ribonucleoprotein K | 6 | 2023 | 28 | 2.440 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 9 | 2017 | 525 | 1.300 |
Why?
|
| Leukemia, Myeloid, Acute | 12 | 2024 | 7273 | 0.910 |
Why?
|
| Tumor Suppressor Protein p53 | 14 | 2020 | 3656 | 0.860 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2022 | 28 | 0.810 |
Why?
|
| Lymphoma, B-Cell | 3 | 2021 | 930 | 0.740 |
Why?
|
| RNA-Binding Proteins | 2 | 2022 | 1016 | 0.670 |
Why?
|
| Genes, p53 | 5 | 2010 | 1140 | 0.650 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2022 | 4964 | 0.640 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2016 | 1901 | 0.630 |
Why?
|
| Immunity | 1 | 2021 | 352 | 0.630 |
Why?
|
| Cell Death | 1 | 2021 | 686 | 0.620 |
Why?
|
| Haploinsufficiency | 2 | 2016 | 301 | 0.570 |
Why?
|
| Virus Diseases | 1 | 2021 | 375 | 0.570 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 546 | 0.570 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2021 | 677 | 0.560 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2021 | 9047 | 0.540 |
Why?
|
| Ribonucleoproteins | 1 | 2015 | 116 | 0.490 |
Why?
|
| Cell Cycle Proteins | 6 | 2017 | 2112 | 0.480 |
Why?
|
| Mice | 28 | 2023 | 35413 | 0.470 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2014 | 866 | 0.470 |
Why?
|
| Oncogene Proteins | 1 | 2016 | 366 | 0.460 |
Why?
|
| Animals | 33 | 2023 | 61346 | 0.440 |
Why?
|
| Carcinogenesis | 2 | 2016 | 1034 | 0.420 |
Why?
|
| Genes, ras | 2 | 2014 | 678 | 0.400 |
Why?
|
| Lymphoma | 3 | 2014 | 1516 | 0.390 |
Why?
|
| Proto-Oncogene Proteins c-myc | 5 | 2021 | 843 | 0.380 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2016 | 2618 | 0.370 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2021 | 5776 | 0.360 |
Why?
|
| Anemia, Macrocytic | 1 | 2010 | 12 | 0.360 |
Why?
|
| B-Lymphocytes | 2 | 2021 | 1419 | 0.340 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2017 | 4642 | 0.340 |
Why?
|
| Protein Binding | 4 | 2022 | 3472 | 0.340 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2010 | 275 | 0.320 |
Why?
|
| Pyrazoles | 2 | 2016 | 1551 | 0.300 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2022 | 5417 | 0.300 |
Why?
|
| Nuclear Proteins | 4 | 2014 | 3435 | 0.290 |
Why?
|
| Rhabdomyosarcoma | 1 | 2010 | 342 | 0.280 |
Why?
|
| Primary Myelofibrosis | 3 | 2022 | 914 | 0.280 |
Why?
|
| DNA Damage | 6 | 2013 | 1991 | 0.280 |
Why?
|
| Disease Models, Animal | 6 | 2021 | 7311 | 0.260 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2021 | 2454 | 0.260 |
Why?
|
| Mutation | 9 | 2021 | 15905 | 0.260 |
Why?
|
| Proteomics | 4 | 2022 | 1425 | 0.260 |
Why?
|
| Apoptosis | 7 | 2022 | 7755 | 0.250 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2022 | 838 | 0.240 |
Why?
|
| Cell Line, Tumor | 7 | 2022 | 14876 | 0.240 |
Why?
|
| Pyrimidines | 2 | 2016 | 3671 | 0.230 |
Why?
|
| Monocytes | 2 | 2019 | 784 | 0.230 |
Why?
|
| Biochemistry | 1 | 2004 | 21 | 0.230 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2023 | 24 | 0.230 |
Why?
|
| Phosphotransferases | 1 | 2004 | 82 | 0.230 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 1956 | 0.220 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 2488 | 0.220 |
Why?
|
| DNA Polymerase II | 1 | 2003 | 58 | 0.220 |
Why?
|
| Sulfonamides | 2 | 2024 | 1942 | 0.220 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2010 | 930 | 0.220 |
Why?
|
| Neoplasms, Experimental | 5 | 2017 | 784 | 0.210 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2004 | 264 | 0.210 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2022 | 115 | 0.200 |
Why?
|
| Fibroblasts | 2 | 2019 | 1647 | 0.190 |
Why?
|
| Aging | 1 | 2009 | 1530 | 0.190 |
Why?
|
| Humans | 35 | 2024 | 270602 | 0.190 |
Why?
|
| Leukemia | 1 | 2010 | 1719 | 0.190 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 2 | 2023 | 115 | 0.190 |
Why?
|
| Immune Evasion | 1 | 2021 | 72 | 0.190 |
Why?
|
| S Phase | 1 | 2001 | 289 | 0.180 |
Why?
|
| Protein Array Analysis | 3 | 2019 | 503 | 0.180 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2022 | 288 | 0.180 |
Why?
|
| G1 Phase | 1 | 2001 | 306 | 0.180 |
Why?
|
| Galectin 1 | 1 | 2020 | 20 | 0.180 |
Why?
|
| Serine | 1 | 2001 | 390 | 0.170 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2022 | 469 | 0.170 |
Why?
|
| Interferon-gamma | 1 | 2024 | 1169 | 0.170 |
Why?
|
| Cell Proliferation | 3 | 2017 | 7232 | 0.170 |
Why?
|
| Mice, Inbred C57BL | 7 | 2017 | 7050 | 0.170 |
Why?
|
| DNA Replication | 1 | 2003 | 768 | 0.170 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2024 | 1024 | 0.160 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 3707 | 0.160 |
Why?
|
| Splenomegaly | 1 | 2019 | 173 | 0.160 |
Why?
|
| Cell Line | 4 | 2017 | 5313 | 0.160 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2020 | 271 | 0.160 |
Why?
|
| Phosphorylation | 7 | 2018 | 4907 | 0.150 |
Why?
|
| Chromatin | 1 | 2003 | 1044 | 0.150 |
Why?
|
| E2F6 Transcription Factor | 1 | 2017 | 10 | 0.150 |
Why?
|
| Tripartite Motif Proteins | 2 | 2014 | 46 | 0.150 |
Why?
|
| Hyperplasia | 1 | 2019 | 571 | 0.150 |
Why?
|
| RNA | 1 | 2022 | 1058 | 0.150 |
Why?
|
| Signal Transduction | 5 | 2016 | 12042 | 0.140 |
Why?
|
| Galectin 3 | 1 | 2018 | 131 | 0.140 |
Why?
|
| Mice, Transgenic | 4 | 2020 | 4203 | 0.140 |
Why?
|
| Tandem Repeat Sequences | 1 | 2017 | 203 | 0.140 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 3 | 2004 | 437 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 4 | 2013 | 3205 | 0.140 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 5581 | 0.140 |
Why?
|
| Cell Cycle | 4 | 2010 | 2134 | 0.140 |
Why?
|
| Angiopoietin-1 | 1 | 2016 | 20 | 0.140 |
Why?
|
| Bone Marrow | 3 | 2020 | 2440 | 0.130 |
Why?
|
| Antigens, CD | 1 | 2021 | 1420 | 0.130 |
Why?
|
| Up-Regulation | 2 | 2021 | 2413 | 0.130 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 5144 | 0.130 |
Why?
|
| Bone Marrow Cells | 1 | 2019 | 965 | 0.130 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2019 | 456 | 0.120 |
Why?
|
| Phenotype | 4 | 2021 | 6501 | 0.120 |
Why?
|
| Heterografts | 1 | 2017 | 738 | 0.120 |
Why?
|
| Azoxymethane | 1 | 2014 | 44 | 0.120 |
Why?
|
| Cell Survival | 2 | 2020 | 3058 | 0.120 |
Why?
|
| Prognosis | 7 | 2024 | 22520 | 0.120 |
Why?
|
| Immunocompromised Host | 1 | 2019 | 718 | 0.120 |
Why?
|
| Gene Expression | 2 | 2020 | 3606 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 538 | 0.120 |
Why?
|
| Gene Knockout Techniques | 1 | 2015 | 267 | 0.120 |
Why?
|
| Receptors, Endothelin | 1 | 2014 | 25 | 0.120 |
Why?
|
| Receptors, Angiotensin | 1 | 2014 | 45 | 0.120 |
Why?
|
| Neoplasms | 5 | 2021 | 15931 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2015 | 298 | 0.120 |
Why?
|
| Chromosomal Instability | 1 | 2015 | 228 | 0.120 |
Why?
|
| Loss of Heterozygosity | 1 | 2016 | 623 | 0.120 |
Why?
|
| Mice, Inbred NOD | 3 | 2021 | 896 | 0.110 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2014 | 191 | 0.110 |
Why?
|
| Cluster Analysis | 1 | 2016 | 1076 | 0.110 |
Why?
|
| Adenine | 1 | 2016 | 674 | 0.110 |
Why?
|
| Feedback, Physiological | 1 | 2013 | 191 | 0.110 |
Why?
|
| Peptide Hydrolases | 1 | 2014 | 258 | 0.100 |
Why?
|
| Fatty Liver | 1 | 2014 | 248 | 0.100 |
Why?
|
| Longevity | 1 | 2013 | 155 | 0.100 |
Why?
|
| Alleles | 2 | 2017 | 2597 | 0.100 |
Why?
|
| RNA, Neoplasm | 1 | 2014 | 805 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 6257 | 0.100 |
Why?
|
| DNA-Binding Proteins | 4 | 2007 | 4992 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 3924 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 12038 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2022 | 4105 | 0.100 |
Why?
|
| Disease Progression | 4 | 2016 | 6867 | 0.090 |
Why?
|
| Inflammation | 1 | 2021 | 2492 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2011 | 506 | 0.090 |
Why?
|
| Plicamycin | 1 | 2010 | 28 | 0.090 |
Why?
|
| Lipids | 1 | 2014 | 650 | 0.090 |
Why?
|
| Mice, SCID | 3 | 2020 | 1825 | 0.090 |
Why?
|
| Cells, Cultured | 2 | 2016 | 5658 | 0.090 |
Why?
|
| Piperidines | 1 | 2016 | 1099 | 0.090 |
Why?
|
| Risk | 1 | 2014 | 1930 | 0.090 |
Why?
|
| Dromaiidae | 1 | 2009 | 4 | 0.090 |
Why?
|
| HeLa Cells | 4 | 2010 | 1683 | 0.090 |
Why?
|
| E2F3 Transcription Factor | 1 | 2009 | 23 | 0.090 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2017 | 1837 | 0.090 |
Why?
|
| Transcription, Genetic | 2 | 2014 | 3328 | 0.080 |
Why?
|
| Sp1 Transcription Factor | 1 | 2010 | 191 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 2419 | 0.080 |
Why?
|
| beta-Galactosidase | 1 | 2009 | 272 | 0.080 |
Why?
|
| THP-1 Cells | 2 | 2020 | 55 | 0.080 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2016 | 809 | 0.080 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 650 | 0.080 |
Why?
|
| Mice, Knockout | 2 | 2016 | 5692 | 0.080 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2014 | 1002 | 0.080 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 10713 | 0.080 |
Why?
|
| Genes, p16 | 1 | 2008 | 132 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 1462 | 0.070 |
Why?
|
| Radiation, Ionizing | 2 | 2013 | 190 | 0.070 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 2012 | 531 | 0.070 |
Why?
|
| DNA Ligases | 1 | 2007 | 67 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 3345 | 0.070 |
Why?
|
| Central Nervous System | 1 | 2009 | 450 | 0.070 |
Why?
|
| Gene Frequency | 1 | 2010 | 1246 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 14021 | 0.070 |
Why?
|
| Syndrome | 1 | 2010 | 1409 | 0.070 |
Why?
|
| Genotype | 1 | 2014 | 4246 | 0.070 |
Why?
|
| Fibrosis | 2 | 2022 | 715 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2020 | 6344 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2015 | 9281 | 0.070 |
Why?
|
| Transcription Factors | 2 | 2023 | 5415 | 0.070 |
Why?
|
| Protein Kinases | 1 | 2009 | 889 | 0.060 |
Why?
|
| Female | 10 | 2020 | 148790 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2010 | 1471 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2015 | 4104 | 0.060 |
Why?
|
| Germ-Line Mutation | 1 | 2010 | 1101 | 0.060 |
Why?
|
| Antigens, CD34 | 2 | 2019 | 639 | 0.060 |
Why?
|
| Protein Stability | 2 | 2016 | 375 | 0.060 |
Why?
|
| Cyclin B | 1 | 2004 | 69 | 0.060 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2007 | 469 | 0.060 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2023 | 51 | 0.060 |
Why?
|
| Precipitin Tests | 1 | 2004 | 347 | 0.060 |
Why?
|
| cdc25 Phosphatases | 1 | 2004 | 101 | 0.050 |
Why?
|
| Ultraviolet Rays | 2 | 2017 | 588 | 0.050 |
Why?
|
| CDC2 Protein Kinase | 1 | 2004 | 188 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2004 | 596 | 0.050 |
Why?
|
| Transcriptome | 1 | 2012 | 1958 | 0.050 |
Why?
|
| Lung | 1 | 2014 | 3284 | 0.050 |
Why?
|
| Endonucleases | 1 | 2004 | 183 | 0.050 |
Why?
|
| Aged | 5 | 2020 | 73534 | 0.050 |
Why?
|
| Male | 8 | 2020 | 128395 | 0.050 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2014 | 2189 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 5595 | 0.050 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2022 | 259 | 0.050 |
Why?
|
| Adult | 5 | 2020 | 81960 | 0.050 |
Why?
|
| Middle Aged | 5 | 2020 | 90450 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2022 | 350 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 4899 | 0.050 |
Why?
|
| Gene Ontology | 1 | 2020 | 80 | 0.040 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2012 | 2636 | 0.040 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 3041 | 0.040 |
Why?
|
| RNA, Small Interfering | 2 | 2020 | 2192 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 10402 | 0.040 |
Why?
|
| Animals, Genetically Modified | 1 | 2021 | 398 | 0.040 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2019 | 90 | 0.040 |
Why?
|
| Hedgehog Proteins | 1 | 2022 | 440 | 0.040 |
Why?
|
| Megakaryocytes | 1 | 2019 | 128 | 0.040 |
Why?
|
| Spleen | 1 | 2020 | 718 | 0.040 |
Why?
|
| Galectins | 1 | 2018 | 73 | 0.040 |
Why?
|
| DNA Repair | 2 | 2004 | 1906 | 0.040 |
Why?
|
| Adoptive Transfer | 1 | 2019 | 431 | 0.040 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2020 | 586 | 0.040 |
Why?
|
| Protein Interaction Maps | 1 | 2018 | 151 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 14638 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2017 | 197 | 0.040 |
Why?
|
| Blood Proteins | 1 | 2018 | 297 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2010 | 3155 | 0.030 |
Why?
|
| Keratinocytes | 1 | 2017 | 244 | 0.030 |
Why?
|
| Serum Amyloid P-Component | 1 | 2016 | 31 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2018 | 626 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2019 | 593 | 0.030 |
Why?
|
| Carcinogens | 1 | 2017 | 390 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 10267 | 0.030 |
Why?
|
| Proteins | 1 | 2004 | 2030 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2022 | 1132 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2001 | 4532 | 0.030 |
Why?
|
| Models, Biological | 1 | 2004 | 3186 | 0.030 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2014 | 40 | 0.030 |
Why?
|
| COP9 Signalosome Complex | 1 | 2014 | 79 | 0.030 |
Why?
|
| Janus Kinase 2 | 1 | 2019 | 755 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2020 | 2033 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 6639 | 0.030 |
Why?
|
| Protein Denaturation | 1 | 2013 | 73 | 0.030 |
Why?
|
| Doxorubicin | 2 | 2011 | 3145 | 0.030 |
Why?
|
| Gene Knock-In Techniques | 1 | 2013 | 183 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 15270 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 2360 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 2179 | 0.020 |
Why?
|
| Survival Rate | 2 | 2016 | 12527 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2014 | 578 | 0.020 |
Why?
|
| Skin | 1 | 2017 | 1281 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1072 | 0.020 |
Why?
|
| Remission Induction | 1 | 2018 | 3658 | 0.020 |
Why?
|
| Young Adult | 3 | 2018 | 22219 | 0.020 |
Why?
|
| Nitriles | 1 | 2016 | 939 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2016 | 1124 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2016 | 2986 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2018 | 5759 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 2016 | 1754 | 0.020 |
Why?
|
| Biopsy | 1 | 2018 | 3491 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2014 | 1127 | 0.020 |
Why?
|
| Zinostatin | 1 | 2009 | 4 | 0.020 |
Why?
|
| E2F5 Transcription Factor | 1 | 2009 | 8 | 0.020 |
Why?
|
| E2F2 Transcription Factor | 1 | 2009 | 27 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2013 | 639 | 0.020 |
Why?
|
| E2F4 Transcription Factor | 1 | 2009 | 30 | 0.020 |
Why?
|
| Adolescent | 3 | 2019 | 32684 | 0.020 |
Why?
|
| Genes, myc | 1 | 2011 | 372 | 0.020 |
Why?
|
| Codon | 1 | 2010 | 260 | 0.020 |
Why?
|
| Chickens | 1 | 2010 | 780 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 2028 | 0.020 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2009 | 169 | 0.020 |
Why?
|
| Blast Crisis | 1 | 2012 | 588 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2009 | 323 | 0.020 |
Why?
|
| E2F1 Transcription Factor | 1 | 2009 | 198 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2010 | 389 | 0.020 |
Why?
|
| Oncogenes | 1 | 2011 | 697 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 3464 | 0.020 |
Why?
|
| Replication Protein C | 1 | 2007 | 22 | 0.020 |
Why?
|
| Actins | 1 | 2010 | 586 | 0.020 |
Why?
|
| DNA Ligase ATP | 1 | 2007 | 53 | 0.020 |
Why?
|
| Etoposide | 1 | 2009 | 907 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2007 | 144 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2008 | 233 | 0.020 |
Why?
|
| DNA | 2 | 2007 | 3042 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2007 | 210 | 0.020 |
Why?
|
| Heterozygote | 1 | 2010 | 1057 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 7643 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2013 | 1362 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 1003 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 31084 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2009 | 741 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2009 | 898 | 0.020 |
Why?
|
| Liver | 1 | 2014 | 3056 | 0.010 |
Why?
|
| Rad52 DNA Repair and Recombination Protein | 1 | 2004 | 11 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 1456 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2007 | 656 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2010 | 1476 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 4317 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2004 | 649 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 1276 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 1469 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2004 | 1801 | 0.010 |
Why?
|
| Incidence | 1 | 2010 | 5825 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2008 | 5318 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2010 | 9460 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 16719 | 0.010 |
Why?
|
| United States | 1 | 2010 | 15827 | 0.010 |
Why?
|